Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesCipher Pharmaceuticals Inc

Cipher Pharmaceuticals Inc

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
13.0 CAD -0.03 ( 0.23%)
Last update at 2026-11-05T14:45:00Z
VOLUME
1700
Market Cap
465.53M
P/E
12.74

Momentum Score

…

Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibrillation to sinus rhythm in adults; Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with acute coronary syndrome; and Natroba for the topical treatment of head lice and scabies infestations in adult and pediatric patients. The company's licensed products comprise Absorica, an oral retinoid for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Conzip, an opioid agonist for the management of moderate to moderately severe chronic pain in adults; and Lipofen, an adjunctive therapy to diet to reduce elevated LDL-C, total-C, triglycerides, and Apo B, as well as to increase HDL-C. Its pipeline products include piclidenoson CF-101, a novel chemical entity for moderate to severe plaque psoriasis and rheumatoid arthritis; MOB-015, a topical formulation of terbinafine, which is in phase 3 clinical trial for treatment of onychomycosis; and DTR-001, a tattoo removal cream. The company was founded in 2000 and is headquartered in Mississauga, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
13.00
Low
13.15
High
52 Week Price Range
11.66
Low
19.63
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Cipher Pharmaceuticals Inc is a Canadian specialty pharmaceutical company that licenses, develops and commercializes prescription medicines in Canada and selected international markets. Long-term growth may be driven by new product launches, in-licensing deals and scaling sales through its commercial channels, which may appeal to investors seeking exposure to recurring branded-drug revenue.
Material risks include regulatory and reimbursement uncertainty, concentration on a few products and partners, competitive pricing pressure and limited scale and financing flexibility typical of small-cap specialty pharma.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
13.03
Dividend Yield
-
Revenue TTM
50.45M
Revenue Per Share
1.98
Gross Profit TTM
40.42M
Debt / Equity
0.04
ROE
23.91%
Net Debt
-1.98M
ROCE
12.80%
Diluted EPS TTM
1.44

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 17.46M 2.96M 12.68M 11.48M 11.06M
Net income 27.81M 11.54M 20.38M 26.64M 7.76M
Selling general administrative 16.30M 10.69M 4.67M 5.54M 5.11M
Selling and marketing expenses - 1.55M 0.75M - -
Gross profit 33.77M 24.10M 17.09M 16.68M 18.26M
Reconciled depreciation 7.23M 4.02M 1.23M 0.99M 0.70M
Ebit - 7.85M 10.30M 11.09M 11.82M
Ebitda 16.80M 11.87M 11.53M 12.07M 12.52M
Depreciation and amortization - 4.02M 1.23M 0.99M 0.70M
Operating income 16.80M 7.85M 11.53M 11.09M 11.82M
Other operating expenses 34.53M 25.52M 9.63M 9.62M 10.13M
Interest expense 1.19M - - 0.46M 0.09M
Tax provision -10.17M -8.59M -7.70M -15.16M 3.30M
Interest income - 2.18M 1.87M 0.43M 0.01M
Net interest income -1.17M 0.33M 1.87M 0.46M -0.08M
Extraordinary items - - - - 0.00M
Income tax expense -10.34M -8.59M -7.70M -15.16M 3.30M
Total revenue 51.33M 33.36M 21.16M 20.68M 21.94M
Total operating expenses 16.97M 16.25M 5.56M 5.63M 6.45M
Cost of revenue 17.56M 9.26M 4.07M 3.99M 3.68M
Total other income expense net 0.66M -4.89M 1.15M 0.39M -0.76M
Net income from continuing ops 27.33M 11.54M 20.38M 26.64M 7.76M
Net income applicable to common shares - 11.54M 20.38M 26.64M 7.76M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 156.22M 162.51M 86.03M 73.78M 51.65M
Intangible assets 71.88M 78.75M 1.76M 2.75M 3.65M
Other current assets 1.16M 0.99M 0.38M 0.37M 0.47M
Total liab 30.20M 60.17M 5.51M 9.70M 12.75M
Total stockholder equity 126.01M 102.34M 80.52M 64.08M 38.90M
Other current liab 18.33M - - 4.90M 6.23M
Common stock 27.81M - 18.01M 17.72M 18.12M
Capital stock 27.86M 27.68M 18.01M 17.72M 18.12M
Retained earnings 99.93M 77.65M 66.27M 50.52M 25.20M
Good will 17.42M 17.45M 15.71M 15.71M 15.71M
Other assets - - - 16.67M 2.47M
Cash 7.48M 17.84M 39.83M 28.84M 20.55M
Total current liabilities 25.00M 19.87M 5.25M 9.37M 12.29M
Current deferred revenue - - 0.52M 0.26M 0.45M
Net debt -1.98M 22.16M -39.47M -28.41M -20.03M
Short term debt 0.29M - 0.09M 0.10M 0.06M
Short long term debt total 5.49M - 0.35M 0.43M 0.52M
Other stockholder equity 7.77M - 5.75M 5.36M 5.09M
Property plant equipment - - - 0.48M 0.50M
Total current assets 28.00M 38.48M 48.27M 38.16M 29.33M
Net tangible assets - - - 45.62M 19.54M
Net receivables 11.19M 13.86M 5.09M 6.80M 6.66M
Long term debt 5.00M 40.00M - - -
Inventory 8.18M 5.79M 2.98M 2.15M 1.65M
Accounts payable 6.38M 5.87M 4.64M 4.11M 5.55M
Accumulated other comprehensive income -9.50M - -9.51M -9.51M -9.51M
Non currrent assets other 0.24M - 19.89M - -
Non current assets total 128.22M 124.03M 37.76M 35.62M 22.32M
Capital lease obligations 0.51M 0.58M 0.35M 0.43M 0.52M
Long term debt total - - - 0.33M 0.46M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -80.04M -0.14M -0.08M 0.00M
Change to liabilities - - - -1.64M -1.09M
Total cashflows from investing activities -0.07M -80.04M -0.14M -0.08M -0.08M
Net borrowings -35.31M 39.79M -0.11M -0.06M -0.83M
Total cash from financing activities -41.18M 39.30M -5.24M -1.91M -2.47M
Change to operating activities - - - 0.10M 0.37M
Net income 27.81M 11.54M 20.38M 26.64M 7.76M
Change in cash -11.20M -21.99M 10.99M 8.29M 11.41M
Begin period cash flow 18.68M 39.83M 28.84M 20.55M 9.14M
End period cash flow 7.48M 17.84M 39.83M 28.84M 20.55M
Total cash from operating activities 30.25M 19.55M 16.00M 10.57M 13.81M
Issuance of capital stock - 0.00M 0.00M - -
Depreciation 7.23M 4.02M 1.23M 0.99M 0.70M
Other cashflows from investing activities - -80.00M -0.12M - -
Change to inventory -2.44M 3.60M -0.83M -0.50M -0.76M
Change to account receivables 2.70M -8.77M 1.71M -0.14M 2.56M
Sale purchase of stock -5.48M -0.18M -5.56M -1.99M -1.72M
Other cashflows from financing activities -0.31M -0.32M 0.43M 0.13M 0.07M
Change to netincome - - - -14.02M 0.68M
Capital expenditures 0.03M 0.04M 0.14M 0.08M 0.08M
Change in working capital 5.32M 8.95M -3.28M -3.03M 4.68M
Stock based compensation 1.74M 1.07M 1.19M 0.40M 0.14M
Other non cash items -2.88M 2.60M -0.79M -0.11M 0.65M
Free cash flow 30.22M 19.50M 15.98M 10.49M 13.81M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(CAD)
Price
(CAD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
CPH
Cipher Pharmaceuticals Inc		 -0.03
0.23%		 13.00 12.74 14.22 9.23 2.69 6.72 14.07
CURA
Curaleaf Holdings Inc.		 -0.27
2.01%		 13.13 - 138.89 2.57 3.14 2.47 13.10
BHC
Bausch Health Companies Inc		 -0.05
0.43%		 11.62 13.98 1.35 0.28 18.74 2.12 6.84
CRON
Cronos Group Inc		 0.17
3.45%		 5.10 - 32.15 9.80 0.95 1.47 1.90
TLRY
Tilray Inc		 -0.25
6.02%		 3.90 - 1000.00 1.28 0.53 1.08 -2.30

Profile*

Cipher Pharmaceuticals Inc

Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibrillation to sinus rhythm in adults; Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with acute coronary syndrome; and Natroba for the topical treatment of head lice and scabies infestations in adult and pediatric patients. The company's licensed products comprise Absorica, an oral retinoid for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Conzip, an opioid agonist for the management of moderate to moderately severe chronic pain in adults; and Lipofen, an adjunctive therapy to diet to reduce elevated LDL-C, total-C, triglycerides, and Apo B, as well as to increase HDL-C. Its pipeline products include piclidenoson CF-101, a novel chemical entity for moderate to severe plaque psoriasis and rheumatoid arthritis; MOB-015, a topical formulation of terbinafine, which is in phase 3 clinical trial for treatment of onychomycosis; and DTR-001, a tattoo removal cream. The company was founded in 2000 and is headquartered in Mississauga, Canada.

5750 Explorer Drive, Mississauga, ON, Canada, L4W 0A9

905 602 5840

https://www.cipherpharma.com

Name Title Year Born
Mr. Craig J. Mull Interim CEO & Chairman NA
Dr. Diane Gajewczyk VP of Scientific & Medical Affairs NA
Mr. Bryan Jacobs Chief Financial Officer NA
Mr. Emilio Presti Director of Sales, Marketing & Hospital Bus. NA
Chuoru Li Corp. Controller NA
David Miller Director of Fin. NA
Mr. Craig J. Mull Interim CEO & Chairman of the Board NA
Mr. Emilio Presti Director of Sales & Marketing NA
Dr. Hamed Ghanei Chief Business Officer NA
Mr. Bryan Jacobs President NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

THX
CAD 1.01
+9.78%
LIF
CAD 21.88
+7.84%
CIA
CAD 2.04
+6.25%
MDA
CAD 38.77
+5.76%
SXGC
CAD 8.56
+5.42%
GIL
CAD 46.32
-23.36%
NOA
CAD 12.40
-22.50%
ITH
CAD 1.95
-20.08%
TNZ
CAD 53.00
-14.24%
LSPD
CAD 14.00
-13.26%

Equity Sectors*

  • Basic Materials

    +0.02%

  • Communication Services

    +1.01%

  • Consumer Cyclical

    -1.14%

  • Consumer Defensive

    -0.06%

  • Energy

    -0.86%

  • Financial Services

    -0.32%

  • Healthcare

    -0.69%

  • Industrials

    -1.25%

  • Real Estate

    +0.16%

  • Technology

    -1.66%

  • Utilities

    -0.04%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…